Welcome to our dedicated page for Precision BioSciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision BioSciences stock.
Precision BioSciences, Inc., based in Durham, North Carolina, is a pioneering biotechnology company dedicated to enhancing life through advanced genome editing. The company employs its proprietary genome editing platform, ARCUS, to develop innovative product candidates aimed at treating human diseases and offering solutions in food and agriculture.
ARCUS, distinguished by its compact size, enables the delivery of gene edits to a broader range of cells and tissues using both viral and non-viral methods. This versatility makes it a robust tool in Precision BioSciences' mission to address various health conditions and agricultural challenges.
The company has recently made significant strides in its projects, partnering with multiple organizations to expand its research and product development capabilities. These collaborations have been pivotal in propelling forward the potential applications of ARCUS technology.
Precision BioSciences is actively engaged in several cutting-edge projects that underscore its commitment to innovation. The company's financial health is reflected in its consistent investment in research and development, ensuring sustained growth and advancement in its technology.
Latest News:
- Source: iECURE, Inc.
- Source: Precision BioSciences, Inc.
- Source: Precision BioSciences
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announces the commencement of a proposed underwritten public offering of its common stock and warrants. The offering includes pre-funded warrants and grants underwriters an option to purchase additional shares. Guggenheim Securities, LLC is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.24%
Tags
-
News
Rhea-AI Summary
Precision BioSciences (DTIL) grants Caribou Biosciences a license for gene editing therapy patents. The agreement includes upfront payment, royalties, and milestone payments for commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.28%
Tags
-
Rhea-AI Summary
Precision BioSciences receives positive regulatory feedback for PBGENE-HBV program, advancing towards clinical development. Expected to be the first potentially curative gene editing program targeting Chronic Hepatitis B.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) promotes Naresh Tanna to Vice President of Investor Relations to enhance and expand its IR program. Tanna, with over 18 years of diverse experience in Oncology, Infectious Diseases, and Rare Diseases, will lead communications with shareholders. His promotion follows Mei Burris' elevation to Senior Director of Finance and Corporate Controller in September 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
-
Rhea-AI Summary
Precision BioSciences (DTIL) receives upfront cash payment and equity investment from TG Therapeutics (TGTX) for an exclusive license to develop Azercabtagene Zapreleucel for autoimmune diseases, with potential payments totaling $17.5 million. Precision also expects to receive up to $288 million in milestone payments and royalties on net sales, extending its cash runway into the first half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announces a 1-for-30 reverse stock split to increase per share market price and meet Nasdaq listing requirements. The split will be effective on February 13, 2024, with trading under the existing symbol 'DTIL'. Shareholders will receive one new share for every 30 shares held.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) has completed a strategic transaction with TG Therapeutics, Inc. to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases. Precision will receive $17.5 million upfront and near-term payments, with potential for up to $288 million in other development milestone payments. The upfront cash and near-term payments are expected to extend Precision’s cash runway into the first half of 2026 and fund Precision’s Wholly-Owned In Vivo Gene Editing Programs through PBGENE-HBV and PBGENE-PMM Phase I Clinical Data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) partner iECURE receives clearance from Australian Therapeutic Goods Administration for Phase 1/2 study of ECUR-506 for the treatment of Ornithine Transcarbamylase (OTC) deficiency. The approval marks a significant milestone for patients and the company, with promising preclinical results indicating the potential for a curative treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
-
Rhea-AI Summary
iECURE, Inc. (ECUR) announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Clinical Trial Notification (CTN) for ECUR-506, an investigational therapy for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric patients. The CTN approval represents the first of such regulatory approvals to begin clinical trials, with additional approvals expected in 2024. The company is in the process of preparing sites for the global, first-in-human Phase 1/2 clinical study and anticipates initiation of such clinical trial in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced the publication in Nature Metabolism of a peer-reviewed manuscript supporting the development of the PBGENE-PMM in vivo gene editing program as a potentially curative therapeutic approach for patients with m.3243-associated primary mitochondrial myopathy. The publication validates the unique ability of ARCUS genome editing to target and eliminate mutant m.3243G mitochondrial DNA with high specificity, leading to an overall improvement in mitochondrial function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
FAQ
What is the current stock price of Precision BioSciences (DTIL)?
The current stock price of Precision BioSciences (DTIL) is $4.72 as of December 20, 2024.
What is the market cap of Precision BioSciences (DTIL)?
The market cap of Precision BioSciences (DTIL) is approximately 34.9M.
What does Precision BioSciences, Inc. do?
Precision BioSciences is a biotechnology company that uses its ARCUS genome editing platform to develop treatments for human diseases and provide agricultural solutions.
Where is Precision BioSciences, Inc. located?
The company is based in Durham, North Carolina, United States.
What is ARCUS?
ARCUS is Precision BioSciences' proprietary genome editing platform, known for its small size and ability to deliver gene edits to various cells and tissues.
What are some recent achievements of Precision BioSciences?
The company has advanced its product candidates and formed partnerships to expand its research and development, showcasing the potential of ARCUS technology.
What is the focus of Precision BioSciences' current projects?
The company is focused on developing treatments for human diseases and offering innovative solutions in food and agriculture through its genome editing platform.
How does ARCUS differ from other genome editing tools?
ARCUS is unique due to its relatively small size, which allows it to target a wider range of cells and tissues using both viral and non-viral delivery methods.
Who are some partners of Precision BioSciences?
Precision BioSciences collaborates with organizations like iECURE, Inc. to enhance its research and development capabilities.
What kind of financial strategy does Precision BioSciences employ?
The company consistently invests in research and development to drive growth and technological advancement.
What is the significance of Precision BioSciences' work in agriculture?
The company aims to provide agricultural solutions that can improve food production and sustainability through advanced genome editing.
How does Precision BioSciences contribute to human health?
By developing innovative treatments for various diseases using its ARCUS genome editing platform, Precision BioSciences aims to improve patient outcomes and overall health.
Precision BioSciences, Inc.
Nasdaq:DTIL
DTIL Rankings
DTIL Stock Data
34.94M
6.59M
6.58%
44.7%
3.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
DURHAM